CADL (Candel Therapeutics) GF Score: 30/100 (As of Jul. 18, 2026) — 58% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CADL Candel Therapeutics Inc CADL
30 GF Score
Price $10.17
! 3 Warning Signs
View Full Analysis

What is Candel Therapeutics GF Score?

Candel Therapeutics CADL +7.38% 30 GF Score is 30 as of Jul. 18, 2026, which is 58% above its 10-year median of 19.00. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Candel Therapeutics has the GF Score of 30, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Candel Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Candel Therapeutics  (NAS:CADL) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Candel Therapeutics GF Score Related Terms

CADL vs AURA, RIGL, NVCT: GF Score Comparison

For the Biotechnology subindustry, Candel Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Candel Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's GF Score falls into.


CADL
30GF Score
Candel Therapeutics Inc CADL
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 30 mean?
Candel Therapeutics (CADL) has a GF Score of 30 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Candel Therapeutics and its competitors. This is 58% above median its historical median of 19.00. Over the past decade, Candel Therapeutics' GF Score has ranged from 13.00 to 42.00.
Is Candel Therapeutics' GF Score too high?
Candel Therapeutics' current GF Score of 30 is 58% above median its 10-year median of 19.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 42.00. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' GF Score compare to AURA and RIGL?
Candel Therapeutics' GF Score of 30 can be compared against companies in the Biotechnology industry. Historically, Candel Therapeutics' own GF Score has ranged from 13.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current GF Score is 30, which is 58% above median its own 10-year median of 19.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current GF Score of 30. The current GF Score is 30, which is 58% above median its 10-year median of 19.00. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current GF Score is 30 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Candel Therapeutics Business Description

Address 117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score

Get the complete analysis for CADL

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.17
Price